TY - JOUR
AU - Mangion, Kenneth
AU - Morrow, Andrew J.
AU - Bagot, Catherine
AU - Bayes, Hannah K.
AU - Blyth, Kevin G.
AU - Church, Colin
AU - Corcoran, David
AU - Delles, Christian
AU - Gillespie, Lynsey
AU - Grieve, Douglas
AU - Ho, Antonia
AU - Kean, Sharon
AU - Lang, Ninian N.
AU - Lennie, Vera
AU - Lowe, David J.
AU - Kellman, Peter
AU - Macfarlane, Peter W.
AU - McConnachie, Alex
AU - Roditi, Giles
AU - Sykes, Robert
AU - Touyz, Rhian M.
AU - Sattar, Naveed
AU - Wereski, Ryan
AU - Wright, Sylvia
AU - Berry, Colin
PY - 2020
DA - July
TI - The Chief Scientist Office cardiovascular and pulmonary imaging in SARS Coronavirus disease-19 (CISCO-19) study
JO - Cardiovascular Research
EP - 2196
VL - 116
IS - 14
DO - http://dx.doi.org/10.1093/cvr/cvaa209
AB - Background: COVID-19 is typically a primary respiratory illness with multisystem involvement. The prevalence and clinical significance of cardiovascular and multisystem involvement in COVID-19 remain unclear. Methods: This is a prospective, observational, multicentre, longitudinal, cohort study with minimal selection criteria and a near-consecutive approach to screening. Patients who have received hospital care for COVID-19 will be enrolled within 28 days of discharge. Myocardial injury will be diagnosed according to the peak troponin I in relation to the upper reference limit (URL, 99th centile) (Abbott Architect troponin I assay; sex-specific URL, male: &gt;34 ng/L; female: &gt;16 ng/L). Multisystem, multimodality imaging will be undertaken during the convalescent phase at 28 days post-discharge (Visit 2). Imaging of the heart, lung, and kidneys will include multiparametric, stress perfusion, cardiovascular magnetic resonance imaging, and computed tomography coronary angiography. Health and well-being will be assessed in the longer term. The primary outcome is the proportion of patients with a diagnosis of myocardial inflammation. Conclusion: CISCO-19 will provide detailed insights into cardiovascular and multisystem involvement of COVID-19. Our study will inform the rationale and design of novel therapeutic and management strategies for affected patients.
PB - Oxford University Press
UR - http://eprints.gla.ac.uk/219875/
KW - Coronavirus (COVID-19)
ER